Research programme: cancer therapeutics - Pelican Therapeutics

Drug Profile

Research programme: cancer therapeutics - Pelican Therapeutics

Alternative Names: PTX-15; PTX-25; PTX-35

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pelican Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action T lymphocyte stimulants; Tumour necrosis factor member 25 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 04 Oct 2017 Pelican Therapeutics and Selexis enters into service agreement for SUREtechnologyPlatform™ technology
  • 19 May 2016 Preclinical trials in Cancer in USA (Parenteral) before May 2016
  • 19 May 2016 Pelican Therapeutics announces intention to submit IND to US FDA for PTX 25 in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top